News from the BioRegion STERN

Here you'll find all press releases and news from companies and institutes in the STERN BioRegion.

03/02/2017 | Exyte

New leadership at M+W Group

Changes have been made to M+W Group's executive board. Dr Wolfgang Büchele will be the new CEO and Mr Roberto Penno will be the new COO.
02/14/2017 | Atriva Therapeutics GmbH

Atriva receives seed financing to develop its next generation influenza therapeutic

The next generation of Antiviral Therapies: Led by Stichting Participatie Atriva together with High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received seed financing from Dutch and German private investors to advance Atriva’s antiviral MEK-Inhibitors (Mitogen-activated protein kinase kinase inhibitor) against Influenza into the clinica...
01/09/2017 | immatics biotechnologies GmbH

Amgen and immatics enter strategic collaboration to develop novel bispecific cancer immunotherapies

Arrangement Combines Immatics’ XPRESIDENT® Technology and Amgen’s Proprietary Bispecific Antibody Platform. Immatics to Receive $30 Million Upfront and Potentially Over $1 Billion in Milestone Payments Plus Royalties.
12/06/2016 | Curetis GmbH

Study with CureVac’s RNAdjuvant® Technology Published in Cancer Immunology, Immunotherapy

For the first time, evidence suggests the same vaccine formulation (RNAdjuvant®) may elicit similar potency in both cancer patients and healthy subjects. RNAdjuvant® found to induce IFNgamma release from PBMCs; critical for innate and adaptive immunity including Th1 type T-cell responses.
11/08/2016 | CureVac AG

CureVac Receives Broad Patent for RNAntibody® Technology

CureVac AG today announced that it has been granted a patent (patent No. EP2101823) by the European Patent Office providing broad patent protection for the Company’s RNAntibody® technology.
11/08/2016 | CureVac AG

CureVac Secures an Additional $29.5 Million From Two New Investors

Baden-Württembergische Versorgungsanstalt für Ärzte, Zahnärzte und Tierärzte and Landeskreditbank Baden-Württemberg invest in CureVac‘s development of innovative drugs „made in Baden-Württemberg“

Atriva Therapeutics Announces Upcoming US Patent Issuance for MEK Treatment against Viral Diseases

Atriva Therapeutics GmbH announces that the USPTO issued the Notice of allowance meaning that grant of one of its core patents: “MEK Inhibitors in the treatment of virus diseases” (US Application 14/434,328) is intended. This patent will cover, a method of treating a subject having a viral infection caused by an influenza virus with neuraminidase i...
10/11/2016 | CureVac AG

CureVac Appoints Pierre Kemula as Chief Financial Officer

Mr. Kemula will join CureVac’s management board and will be responsible for leading the company’s financial and capital markets activities. CureVac AG, the most clinically advanced mRNA company, today announced the appointment of Pierre Kemula as Chief Financial Officer (CFO). Mr. Kemula will join CureVac’s management board and will be responsibl...
10/07/2016 | Eberhard Karls Universität Tübingen

How “dead” bacteria return to life

Tübingen researchers discover strict genetic timetable for resuscitation of dormant cells
07/18/2016 | CureVac AG

Study in Peer-Reviewed Journal Vaccine Demonstrates Decoding Mode of Action of mRNA Vaccines

CureVac AG, the most clinically advanced mRNA company, today announced that a study of its RNActive® technology was published in the renowned, peer-reviewed journal Vaccine. The study, titled, “Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity,” demonstrated a mechanistic insigh...

Atriva Therapeutics Completes Transfer of Co-Infection Patent

Atriva Therapeutics GmbH announces the acquisition of the co-infection patent (Application Nr: PCT/IB2015/053644) from the University of Muenster, Germany. This patent covers the beneficial and potentially lifesaving use of MEK inhibitors against co-infections of bacteria, including multi-resistant bacterial strains such as MRSA, which often occurs...

First four companies selected to participate in the German Accelerator Life Sciences program in Cambridge

During the 34th JP Morgan Healthcare Conference, the German Accelerator Life Sciences (GALS) announced the first four companies to participate in its Cambridge-based program. AYOXXA Biosystems, PEPperPRINT, Personal MedSystems, and Sonormed will receive support tailored towards the specific needs of each company for up to 12 months. The scope of th...
11/11/2015 | Curetis GmbH

Curetis IPO priced at EUR 10.00 per Share; raises EUR 40 million

Curetis N.V. (The former Curetis B.V. was converted into Curetis N.V. immediately after determination of the final offer price.) (the “Company” and, together with Curetis AG, "Curetis"), a developer of next-level molecular diagnostic solutions, today announces the completion of its initial public offering, which was launched on October 28, 2015 (th...
10/28/2015 | Computomics GmbH

High-Tech Gruenderfonds (HTGF) invests in the agricultural biotechnology startup Computomics GmbH

The non-GMO plant breeding industry increasingly uses high-throughput DNA sequencing to arrive at new crop varieties faster and more efficiently. Computomics offers the cutting-edge bioinformatics analysis services required to efficiently use high-throughput sequencing data. Services include genome assembly and annotation, genomic variation, transc...
09/18/2015 | Biametrics GmbH

Pharmaceutical research and life sciences profit from unique biosensor technology

Biametrics GmbH today announced the completion of their most recent financing round with €3.1 Million. Partners of the A Series Investment were LBBW Venture GmbH, MBG Mittelständische Beteiligungsgesellschaft BW, and KfW Bankengruppe. Together with seed investors HTGF and Seedfonds BW, they are aiming to accelerate the expansion of Biametrics’ bioa...
09/11/2015 | CureVac AG

CureVac Establishes U.S. Operations in Cambridge, MA

CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announced the official launch of its U.S. operations in Cambridge, MA, as the company advances the development of its proprietary mRNA platform technology and multiple, clinical-stage mRNA therapeutics and vaccines.
09/11/2015 | CureVac AG

IAVI and CureVac Partner to Accelerate Development and Testing of AIDS Vaccine Candidates

Novel HIV immunogens to be delivered via novel mRNA platform